We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > thrombocytopaenic purpura

News List

FDA approves Amgen's Nplate for certain paediatric patients with immune thrombocytopaenia firstwordpharma
December 17, 2018
Amgen on Friday announced that the FDA expanded the indication for Nplate (romiplostim) to include its use in paediatric patients aged one year and older with immune thrombocytopaenia (ITP) for at least six months who experienced an insufficient response
FDA approves Amgen's Nplate for certain paediatric patients with immune thrombocytopaenia firstwordpharma
December 17, 2018
Amgen on Friday announced that the FDA expanded the indication for Nplate (romiplostim) to include its use in paediatric patients aged one year and older with immune thrombocytopaenia (ITP) for at least six months who experienced an insufficient response